Advertisement
UK markets close in 3 hours 22 minutes
  • FTSE 100

    8,365.02
    -5.31 (-0.06%)
     
  • FTSE 250

    20,719.87
    +9.80 (+0.05%)
     
  • AIM

    803.89
    +0.02 (+0.00%)
     
  • GBP/EUR

    1.1740
    -0.0007 (-0.06%)
     
  • GBP/USD

    1.2744
    +0.0025 (+0.19%)
     
  • Bitcoin GBP

    54,863.69
    +16.15 (+0.03%)
     
  • CMC Crypto 200

    1,509.72
    +7.05 (+0.47%)
     
  • S&P 500

    5,307.01
    -14.40 (-0.27%)
     
  • DOW

    39,671.04
    -201.95 (-0.51%)
     
  • CRUDE OIL

    78.10
    +0.53 (+0.68%)
     
  • GOLD FUTURES

    2,369.90
    -23.00 (-0.96%)
     
  • NIKKEI 225

    39,103.22
    +486.12 (+1.26%)
     
  • HANG SENG

    18,868.71
    -326.89 (-1.70%)
     
  • DAX

    18,731.39
    +51.19 (+0.27%)
     
  • CAC 40

    8,116.65
    +24.54 (+0.30%)
     

GenSight Biologics Announces the Filing of its 2023 Universal Registration Document

PARIS, April 18, 2024--(BUSINESS WIRE)--Regulatory News:

GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the filing of its 2023 Universal Registration Document (URD) in English with the French market authority (Autorités des Marchés Financiers, or AMF) under the reference D.24-0299.

The universal registration document notably includes:

  • the 2023 annual financial report;

  • the management report;

  • the report on corporate governance; and

  • the description of the share buyback program.

ADVERTISEMENT

This universal registration document may be consulted on the Company’s website (www.gensight-biologics.com), "Investors" section, and on the AMF’s website (www.amf-france.org).

About GenSight Biologics

GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics’ lead product candidate, LUMEVOQ® (GS010; lenadogene nolparvovec), is an investigational compound and has not been registered in any country at this stage, developed for the treatment of Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease affecting primarily teens and young adults that leads to irreversible blindness. Using its gene therapy-based approach, GenSight Biologics’ product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240418994025/en/

Contacts

GenSight Biologics
Chief Financial Officer
Ivan Tortet
itortet@gensight-biologics.com

LifeSci Advisors
Investor relations
Guillaume van Renterghem
gvanrenterghem@lifesciadvisors.com
+41 (0)76 735 01 31